Year: 2012
Type: article
Abstract: In their study of FRA in lung adenocarcinoma, O'Shannessy et al employed rigorous validation of a potentially useful clinical tool--using an immunohistochemical assay with a specific monoclonal antibody, they show that FRA expression is relatively specific for lung adenocarcinoma and that high FRA expression is associated with improved survival. Though further work will be necessary to translate this assay (and the related targeted therapy) into human cancer patients, their study confirmed the potential of FRA as a prognostic marker in lung adenocarcinoma.
Source: Oncotarget
Author: Laura D. Wood
Institutions: Johns Hopkins University, Johns Hopkins Medicine
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W1663596625